Skip to search formSkip to main contentSkip to account menu

GSK2485852

Known as: GSK5852 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Boronic AcidsSulfonamides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Design of N-Benzoxaborole Benzofuran GSK8175—Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor
We previously described the discovery of GSK5852 (1), a non-nucleoside polymerase (NS5B) inhibitor of hepatitis C virus (HCV), in… 
2019
2019
Resurrecting the Condemned: Identification of N-Benzoxaborole Benzofuran GSK8175 as a Clinical Candidate with Reduced Metabolic Liability.
Recently, in a program designed to improve the metabolic stability of the HCV inhibitor GSK5852, N-benzoxaborole benzofuran… 
2014
2014
A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically…
This first‐time‐in‐human, randomized, double‐blind, placebo‐controlled, dose‐escalation study assessed the safety, tolerability… 
2013
2013
HCV NS5B GT1A C316Y with GSK5852
2013
2013
HCV NS5B GT1A with GSK5852
2011
2011
820 CD81 EXPRESSION ON LYMPHOCYTE SUBTYPES FOR DISCRIMINATION BETWEEN SUSTAINED VIROLOGIC RESPONSE AND RELAPSE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEG-INTERFERON-ALFA AND RIBAVIRIN
2011
2011
818 PRECLINICAL CHARACTERIZATION OF GSK2485852, A NOVEL HCV POLYMERASE INHIBITOR
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)